Recombinant interferon alpha 2a is effective in the treatment of discoid and subacute cutaneous lupus erythematosus

Br J Dermatol. 1990 Mar;122(3):405-9. doi: 10.1111/j.1365-2133.1990.tb08290.x.

Abstract

Ten patients suffering from either discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) were treated with interferon alpha 2a. Eight received low or intermediate doses (18-45 x 10(6) U/week) for a short period of time (4-8 weeks), with marked improvement of skin lesions in six, an exacerbation in one patient and no change in the other. Two patients with SCLE received high doses (100-120 x 10(6) U/week) over 12 weeks, with complete clearing of the lesions in one and a marked improvement in the other. The responses were of short duration and within a few weeks of stopping treatment all who had improved or cleared relapsed. The side-effects in all the patients were fever and a flu-like syndrome which necessitated a reduction of the dose in one case. In two patients there were increases in the liver enzyme levels, but no haematological toxicity was noted.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Clinical Trials as Topic
  • Drug Administration Schedule
  • Female
  • Humans
  • Interferon Type I / therapeutic use*
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use*
  • Lupus Erythematosus, Cutaneous / therapy*
  • Lupus Erythematosus, Discoid / therapy*
  • Male
  • Middle Aged
  • Recombinant Proteins

Substances

  • Interferon Type I
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins